CoChat

Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth

Open access
Pozo, Natividad, Zahonero, Cristina, Fernández, Paloma, Liñares, Jose M., Ayuso, Angel, Hagiwara, Masatoshi, Pérez, Angel, Ricoy, Jose R., Hernández-Laín, Aurelio, Sepúlveda, Juan M., Sánchez-Gómez, Pilar · 2013 · Journal of Clinical Investigation
Cited by 140

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Glioblastomas (GBMs) are very aggressive tumors that are resistant to conventional chemo- and radiotherapy. New molecular therapeutic strategies are required to effectively eliminate the subpopulation of GBM tumor-initiating cells that are responsible for relapse. Since EGFR is altered in 50% of GBMs, it represents one of the most promising targets; however, EGFR kinase inhibitors have produced poor results in clinical assays, with no clear explanation for the observed resistance. We uncovered a fundamental role for the dual-specificity tyrosine phosphorylation-regulated kinase, DYRK1A, in regulating EGFR in GBMs. We found that DYRK1A was highly expressed in these tumors and that its expression was correlated with that of EGFR. Moreover, DYRK1A inhibition promoted EGFR degradation in primary GBM cell lines and neural progenitor cells, sharply reducing the self-renewal capacity of normal and tumorigenic cells. Most importantly, our data suggest that a subset of GBMs depends on high surface EGFR levels, as DYRK1A inhibition compromised their survival and produced a profound decrease in tumor burden. We propose that the recovery of EGFR stability is a key oncogenic event in a large proportion of gliomas and that pharmacological inhibition of DYRK1A could represent a promising therapeutic intervention for EGFR-dependent GBMs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci63623

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 140

Metadata

Authors
Pozo, N., Zahonero, C., Fernández, P., Liñares, J. M., Ayuso, A., Hagiwara, M., Pérez, A., Ricoy, J. R., Hernández-Laín, A., Sepúlveda, J. M., & Sánchez-Gómez, P.
Venue
Journal of Clinical Investigation
Published
2013-05-01
Volume
123
Issue
6
Pages
2475-2487
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2170311998
Cited by
140
References
4
FWCI
3.55
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth. https://app.cochat.ai/papers/10.1172/jci63623
The paper
Pozo, N., Zahonero, C., Fernández, P., Liñares, J. M., Ayuso, A., Hagiwara, M., Pérez, A., Ricoy, J. R., Hernández-Laín, A., Sepúlveda, J. M., & Sánchez-Gómez, P. (2013). Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth. Journal of Clinical Investigation. https://doi.org/10.1172/jci63623

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.